Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2023
February 2023, Vol 14, No 1
February 2023, Vol 14, No 1
Krazati Receives Accelerated FDA Approval for NSCLC with KRASᴳ¹²ᶜ Mutation
FDA Approvals, News & Updates
,
Lung Cancer
February 2023, Vol 14, No 1
On
December 12, 2022
, the FDA accelerated the approval of adagrasib (Krazati; Mirati Therapeutics), a RAS GTPase inhibitor, for adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and
KRAS
G12C
mutation (as determined by an FDA-approved test) who have received at least 1 systemic therapy.
Read More
Supportive Care and Management of Complications in BTCs: A Multidisciplinary Team Approach
Cholangiocarcinoma
February 2023, Vol 14, No 1
At the 4th Annual Cholangiocarcinoma Summit, held on October 13-15, 2022, in Aurora, CO, experts in the field of gastroenterology, interventional radiology, nursing, and surgery discussed the importance of using a multidisciplinary approach to supportive care and the management of complications in patients with biliary tract cancers (BTCs).
Read More
CTC Count May Help Physicians Choose Treatment for Patients with Metastatic Breast Cancer
By
Wayne Kuznar
SABCS Highlights
,
Breast Cancer
February 2023, Vol 14, No 1
Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive,
HER2
-negative breast cancer, according to results from the STIC CTC trial, which were discussed at the 2022 San Antonio Breast Cancer Symposium (SABCS) by François-Clément Bidard, MD, PhD, Co-Coordinator, Breast Cancer Research, Institut Curie, Paris, France, and Professor, Medicine, Department of Medical Oncology, Institut Curie and Université de Versailles Saint-Quentin-en-Yvelines, France.
Read More
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
Wayne Kuznar
ASH Highlights
,
Multiple Myeloma
February 2023, Vol 14, No 1
Response to treatment with a regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was greater and minimal residual disease (MRD) was achieved more frequently compared with a regimen of lenalidomide plus dexamethasone (Rd) in the first randomized phase 3 clinical trial dedicated to frail, transplant-ineligible patients with newly diagnosed multiple myeloma.
Read More
Restrictive Diet May Not Be Necessary for Patients Undergoing HSCT
By
Phoebe Starr
ASH Highlights
,
Hematologic Malignancies
February 2023, Vol 14, No 1
Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.
Read More
Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma
FDA Approvals, News & Updates
February 2023, Vol 14, No 1
On
December 9, 2022
, the FDA approved atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, for patients aged ≥2 years with unresectable or metastatic alveolar soft-part sarcoma (ASPS), a type of soft-tissue sarcoma.
Read More
Brukinsa Now FDA Approved for Patients with CLL or SLL
FDA Approvals, News & Updates
,
Leukemia
,
Lymphoma
February 2023, Vol 14, No 1
On
January 19, 2023
, the FDA approved zanubrutinib (Brukinsa; BeiGene USA), a Bruton tyrosine kinase (BTK) inhibitor, for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The FDA granted zanubrutinib an orphan drug designation for this indication.
Read More
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive, Unresectable or Metastatic Colorectal Cancer
FDA Approvals, News & Updates
,
Colorectal Cancer
February 2023, Vol 14, No 1
On
January 19, 2023
, the FDA accelerated the approval of tucatinib (Tukysa; Seagen), a Bruton tyrosine kinase inhibitor, in combination with trastuzumab (Herceptin), a HER2/
neu
receptor agonist, for the treatment of
RAS
wild-type,
HER2
-positive, unresectable or metastatic colorectal cancer (CRC) that progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies.
Read More
Keytruda Received FDA Approval for Adjuvant Treatment of NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
February 2023, Vol 14, No 1
On
January 26, 2023
, the FDA approved pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non–small-cell lung cancer (NSCLC), after resection and platinum-based chemotherapy.
Read More
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer
FDA Approvals, News & Updates
,
Bladder Cancer
,
Genitourinary Cancers
February 2023, Vol 14, No 1
On
December 22, 2022
, the FDA accelerated the approval of mosunetuzumab-axgb (Lunsumio; Genentech), a bispecific CD20-directed CD3 T-cell engager, for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication breakthrough therapy and orphan drug designations.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma